◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › ILMN

Illumina Inc (ILMN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-09-19

Illumina Inc (ILMN) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in San Diego, United States with about 8,600 employees. Its market capitalization is roughly $36 billion. In the fiscal year ended 2025-12-31, ILMN reported $4.3B in revenue and $850M in net income.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Interactive charts & full statements → Open the ILMN valuation workbench →

ILMN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.4B	$4.3B	$4.4B	$4.5B	$4.6B	$4.5B	$3.2B	$3.5B	$3.3B	$2.8B	$2.4B	$2.2B	$1.9B	$1.4B	$1.1B	$1.1B	$903M	$666M	$573M	$367M	$185M
Gross Profit	$2.9B	$2.9B	$2.9B	$2.7B	$3.0B	$3.2B	$2.2B	$2.5B	$2.3B	$1.8B	$1.7B	$1.5B	$1.3B	$912M	$774M	$709M	$602M	$461M	$368M	$234M	$125M
Gross Margin %	67.1%	66.7%	65.4%	60.9%	64.8%	69.7%	68.0%	69.6%	69.0%	66.3%	69.5%	69.8%	69.7%	64.2%	67.3%	67.2%	66.6%	69.1%	64.1%	63.9%	67.8%
Operating Income (EBIT)	$919M	$864M	($833M)	($1.1B)	($4.2B)	($123M)	$393M	$985M	$883M	$606M	$587M	$613M	$515M	$134M	$201M	$199M	$212M	$126M	$80M	($301M)	$38M
Operating Margin %	20.9%	19.9%	-19.1%	-23.7%	-91.2%	-2.7%	12.1%	27.8%	26.5%	22.0%	24.5%	27.6%	27.7%	9.4%	17.5%	18.9%	23.4%	18.9%	14.0%	-82.1%	20.5%
Net Income	$853M	$850M	($1.2B)	($1.2B)	($4.4B)	$762M	$656M	$1.0B	$826M	$726M	$463M	$462M	$353M	$125M	$151M	$87M	$125M	$72M	$50M	($278M)	$40M
Net Margin %	19.4%	19.6%	-28.0%	-25.8%	-96.1%	16.8%	20.2%	28.3%	24.8%	26.4%	19.3%	20.8%	19.0%	8.8%	13.2%	8.2%	13.8%	10.8%	8.8%	-75.9%	21.6%
EBITDA	$1.4B	$1.5B	($725M)	($1.1B)	($3.8B)	$128M	$580M	$1.2B	$1.1B	$762M	$735M	$753M	$603M	$297M	$326M	$237M	$252M	$169M	$123M	$18M	$44M
Earnings Per Share (EPS)	$5.51	$5.45	$-7.69	$-7.35	$-28.05	$5.05	$4.43	$6.72	$5.54	$4.91	$3.13	$3.10	$2.37	$0.90	$1.13	$0.62	$0.87	$0.53	$0.38	$-2.57	$0.41
Shares Outstanding (M)	154M	156M	159M	158M	157M	151M	148M	149M	149M	148M	148M	149M	149M	140M	134M	139M	143M	137M	134M	108M	98M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	—	$1.1B	$1.2B	$1.1B	$1.1B	$1.0B	$1.1B	$1.1B	$1.1B
Gross Profit	—	$721M	$778M	$732M	$717M	$685M	$728M	$745M	$721M
Gross Margin %	—	66.1%	67.1%	67.6%	67.8%	65.8%	65.9%	69.0%	64.8%
Operating Income (EBIT)	—	$209M	$257M	$231M	$222M	$184M	$202M	$741M	($1.6B)
Operating Margin %	—	19.2%	22.2%	21.3%	21.0%	17.7%	18.3%	68.6%	-147.2%
Net Income	—	$134M	$334M	$150M	$235M	$131M	$187M	$705M	($2.0B)
Net Margin %	—	12.3%	28.8%	13.9%	22.2%	12.6%	16.9%	65.3%	-178.8%
EBITDA	—	$250M	$471M	$312M	$399M	$253M	$283M	$826M	($1.9B)
Earnings Per Share (EPS)	$1.35	$0.87	$2.17	$0.97	$1.50	$0.82	$1.17	$4.41	$-12.50
Shares Outstanding (M)	—	154M	154M	154M	157M	159M	160M	160M	159M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$1.1B	$1.1B	$837M	$478M	$392M	$545M	$1.1B	$1.1B	$1.1B	$875M	$687M	$660M	$501M	$386M	$292M	$358M	$273M	$174M	$88M	$56M	$39M
Capital Expenditures (CapEx)	$139M	$148M	$128M	$195M	$286M	$208M	$189M	$209M	$296M	$312M	$271M	$143M	$142M	$91M	$81M	$80M	$56M	$55M	$96M	$24M	$15M
Free Cash Flow (FCF)	$989M	$931M	$709M	$283M	$106M	$337M	$891M	$842M	$846M	$563M	$416M	$516M	$359M	$296M	$211M	$279M	$216M	$119M	($8M)	$32M	$24M
FCF Margin %	22.5%	21.5%	16.2%	6.3%	2.3%	7.4%	27.5%	23.8%	25.4%	20.5%	17.3%	23.3%	19.3%	20.8%	18.4%	26.4%	23.9%	17.9%	-1.4%	8.7%	12.9%
Dividends Paid	—	—	—	—	$937M	$511M	—	—	$735M	$5M	$12M	$0M	$1.1B	$125M	$0M	$858M	$0M	$146M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$289M	$321M	$284M	$234M	$240M	$364M	$316M	$80M
Capital Expenditures (CapEx)	$38M	$54M	$24M	$23M	$39M	$29M	$32M	$31M
Free Cash Flow (FCF)	$251M	$267M	$260M	$211M	$201M	$335M	$284M	$49M
FCF Margin %	23.0%	23.0%	24.0%	20.0%	19.3%	30.3%	26.3%	4.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	—	$6.6B	$6.3B	$10.1B	$12.3B	$15.2B	$7.6B	$7.3B	$7.0B	$5.3B	$4.3B	$3.7B	$3.3B	$3.0B	$2.6B	$2.2B	$1.8B	$1.4B	$1.4B	$988M	$301M
Cash & Cash Equivalents	—	$1.4B	$1.1B	$1.0B	$2.0B	$1.2B	$1.8B	$2.0B	$1.1B	$1.2B	$735M	$769M	$636M	$712M	$434M	$303M	$249M	$145M	$327M	$175M	$38M
Total Liabilities	—	$3.9B	$3.9B	$4.4B	$5.7B	$4.5B	$2.9B	$2.7B	$3.1B	$2.3B	$2.0B	$1.8B	$1.9B	$1.5B	$1.2B	$1.1B	$641M	$566M	$529M	$576M	$53M
Total Debt (Short + Long-Term)	—	$2.1B	$2.1B	$1.6B	$2.8B	$1.8B	$1.2B	$1.2B	$2.0B	$1.2B	$1.0B	$1.1B	$1.3B	$869M	$842M	$844M	$390M	$390M	$400M	$400M	$0M
Total Shareholders' Equity	—	$2.7B	$2.4B	$5.7B	$6.6B	$10.7B	$4.7B	$4.6B	$3.8B	$2.8B	$2.3B	$1.8B	$1.5B	$1.5B	$1.3B	$1.1B	$1.2B	$864M	$849M	$412M	$247M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ILMN viewer.

ILMN Metric Deep Dives

Other Companies in DIAGNOSTICS & RESEARCH

NTRA · Natera Inc — $53 billion
GH · Guardant Health Inc — $24 billion
MEDP · Medpace Holdings Inc — $17 billion
ICLR · ICON PLC — $13 billion
TWST · Twist Bioscience Corp — $11 billion
QGEN · Qiagen NV — $9 billion
RDNT · RadNet Inc — $6 billion
SHC · Sotera Health Co — $5 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← ILM1 All “I” companies ILOW →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.